Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 265 participants.
Also called NCT05514548
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 265 participants
- Sponsor
- Registry
-
NCT05514548
-
- Other papers using this trial's data
- A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Georgia, Hungary, Israel, Mexico, Serbia
- Registry status
- Completed
Technical summary
Registry record NCT05514548. Randomized; triple masking; primary purpose treatment. Start 2022-10-19 (actual); primary completion 2024-08-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
- Condition
- Diabetic Kidney Disease
- Intervention (Drug)
- INV-202
- Intervention (Drug)
- Placebo
- Lead sponsor
- Inversago Pharma Inc.
- Collaborator
- Worldwide Clinical Trials
Record details
- Record id
cardio:ct-nct05514548- Content hash
3f1de5ccf3f4866be11bded7297ea9f854c7531218ed7cc097a0de87846f9eb8